According to real-world data, no survival advantage was seen when comparing 3 frontline CDK4/6 inhibitor combinations in ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast, according to 6-year data from the OlympiA trial.

The agency granted approval to durvalumab for the treatment of a subset of patients with limited-stage small cell lung cancer ...

Long-term follow-up showed continued meaningful responses in patients with relapsed or refractory KMT2Ar acute leukemia who ...

An expanded analysis from the phase 3 CEPHEUS trial showed that daratumumab plus VRd improved MRD responses as well as ...

The phase 3 PANOVA-3 trial, designed to evaluate concomitant treatment with tumor treating fields and chemotherapy, met its ...

Meta: Blinatumomab plus chemotherapy, vs chemotherapy alone, significantly improved DFS rates and was well tolerated in ...

According to the American Lung Association, biomarker testing gaps and low screening rates continue to hinder lung cancer ...

By addressing these issues, we can ensure that all patients, regardless of their socioeconomic status, have the opportunity ...

Cadonilimab plus platinum-based chemotherapy improved progression-free and overall survival in advanced cervical cancer ...

Real-world treatment with liso-cel showed a broad spectrum of outcomes that were comparable to those in the pivotal TRANSFORM and PILOT trials in patients with relapsed/refractory large B-cell ...

The FDA has granted fast track designation to LBS-007 for the treatment of patients with acute myeloid leukemia.